Healthcare / Diagnostics & ResearchHKSE
$0.59
-0.01 (-1.67%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 35% · confianza 12%
FCF escenarios
weak_data · normalized FCF $-191.4M · quality 31.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
3/100
F
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$572M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-35.9%
↓Gross Margin
10.5%
↓Debt/Equity
2.06
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-65.9%
FCF CAGR
—
FCF margin
-260.5%
FCF / Net income
2.78x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $73.5M · net income $-68.8M · FCF $-191.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $73.5M | $73.5M | $70.5M | $212.0M | $1.85B |
| Net Income | $-68.8M | $-68.8M | $-198.1M | $-95.4M | $258.1M |
| EBITDA | $-45.8M | $-45.8M | $-214.5M | $-81.1M | $932.7M |
| EPS | -0.07 | -0.07 | -0.20 | -0.10 | 0.27 |
| Gross Margin | 10.5% | 10.5% | -7.0% | 16.2% | 59.5% |
| Operating Margin | -102.4% | -102.4% | -209.4% | -56.0% | 45.9% |
| Net Margin | -93.6% | -93.6% | -281.0% | -45.0% | 13.9% |
| Balance Sheet | |||||
| Debt/Equity | 2.06 | 2.06 | 0.71 | 0.22 | 0.14 |
| Current Ratio | 0.23 | 0.23 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-191.4M | $-191.4M | $-203.5M | $132.3M | $361.2M |
| Returns | |||||
| ROE | -35.9% | -35.9% | -74.8% | -20.6% | 42.8% |
| Valuation | |||||
| P/E | — | — | — | — | 4.10 |
| EV/EBITDA | — | — | — | — | 1.12 |
| P/B | 3.01 | 3.01 | 1.83 | 1.33 | 1.76 |
| Growth & Yield | |||||
| Revenue Growth | 4.2% | 4.2% | -66.7% | -88.6% | — |
| EPS Growth | 65.9% | 65.9% | -107.1% | -136.9% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-14.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.20 → -0.07
Residual
-14.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.